全文获取类型
收费全文 | 1433篇 |
免费 | 71篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 85篇 |
妇产科学 | 33篇 |
基础医学 | 128篇 |
口腔科学 | 16篇 |
临床医学 | 184篇 |
内科学 | 379篇 |
皮肤病学 | 11篇 |
神经病学 | 89篇 |
特种医学 | 94篇 |
外科学 | 121篇 |
综合类 | 44篇 |
预防医学 | 152篇 |
眼科学 | 18篇 |
药学 | 78篇 |
肿瘤学 | 88篇 |
出版年
2018年 | 16篇 |
2017年 | 12篇 |
2016年 | 18篇 |
2015年 | 24篇 |
2014年 | 40篇 |
2013年 | 39篇 |
2012年 | 50篇 |
2011年 | 47篇 |
2010年 | 42篇 |
2009年 | 28篇 |
2008年 | 36篇 |
2007年 | 36篇 |
2006年 | 31篇 |
2005年 | 37篇 |
2004年 | 33篇 |
2003年 | 37篇 |
2002年 | 36篇 |
2001年 | 29篇 |
2000年 | 32篇 |
1999年 | 34篇 |
1998年 | 43篇 |
1997年 | 26篇 |
1996年 | 30篇 |
1995年 | 21篇 |
1994年 | 24篇 |
1993年 | 27篇 |
1992年 | 30篇 |
1991年 | 35篇 |
1990年 | 35篇 |
1989年 | 55篇 |
1988年 | 50篇 |
1987年 | 35篇 |
1986年 | 34篇 |
1985年 | 47篇 |
1984年 | 22篇 |
1983年 | 19篇 |
1982年 | 17篇 |
1981年 | 16篇 |
1980年 | 16篇 |
1979年 | 32篇 |
1978年 | 11篇 |
1976年 | 11篇 |
1975年 | 12篇 |
1973年 | 11篇 |
1972年 | 11篇 |
1959年 | 15篇 |
1958年 | 16篇 |
1957年 | 14篇 |
1955年 | 15篇 |
1954年 | 19篇 |
排序方式: 共有1526条查询结果,搜索用时 46 毫秒
61.
Joanne M. Hildebrand Maria C. Tanzer Isabelle S. Lucet Samuel N. Young Sukhdeep K. Spall Pooja Sharma Catia Pierotti Jean-Marc Garnier Renwick C. J. Dobson Andrew I. Webb Anne Tripaydonis Jeffrey J. Babon Mark D. Mulcair Martin J. Scanlon Warren S. Alexander Andrew F. Wilks Peter E. Czabotar Guillaume Lessene James M. Murphy John Silke 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(42):15072-15077
Necroptosis is considered to be complementary to the classical caspase-dependent programmed cell death pathway, apoptosis. The pseudokinase Mixed Lineage Kinase Domain-Like (MLKL) is an essential effector protein in the necroptotic cell death pathway downstream of the protein kinase Receptor Interacting Protein Kinase-3 (RIPK3). How MLKL causes cell death is unclear, however RIPK3–mediated phosphorylation of the activation loop in MLKL trips a molecular switch to induce necroptotic cell death. Here, we show that the MLKL pseudokinase domain acts as a latch to restrain the N-terminal four-helix bundle (4HB) domain and that unleashing this domain results in formation of a high-molecular-weight, membrane-localized complex and cell death. Using alanine-scanning mutagenesis, we identified two clusters of residues on opposing faces of the 4HB domain that were required for the 4HB domain to kill cells. The integrity of one cluster was essential for membrane localization, whereas MLKL mutations in the other cluster did not prevent membrane translocation but prevented killing; this demonstrates that membrane localization is necessary, but insufficient, to induce cell death. Finally, we identified a small molecule that binds the nucleotide binding site within the MLKL pseudokinase domain and retards MLKL translocation to membranes, thereby preventing necroptosis. This inhibitor provides a novel tool to investigate necroptosis and demonstrates the feasibility of using small molecules to target the nucleotide binding site of pseudokinases to modulate signal transduction.Programmed necrosis or “necroptosis” has emerged in the past 5 years as a cell death mechanism that complements the conventional cell death pathway, apoptosis, in multicellular organisms. In contrast to apoptosis, necroptosis does not appear to serve an important role in multicellular organism development (1–3) but participates in the defense against pathogens and is a likely culprit in destructive inflammatory conditions (4–7). Receptor Interacting Protein Kinase-3 (RIPK3) was identified as a key effector of necroptosis in 2009 (4, 5) and its substrate, the pseudokinase Mixed Lineage Kinase Domain-Like (MLKL), in 2012 (8, 9), but the molecular events following RIPK3-mediated phosphorylation of MLKL required to induce cell death are unclear. The RIPK1/RIPK3/MLKL necrosome has been proposed to activate PGAM5 (phosphoglycerate mutase 5) and Drp1 (Dynamin-related protein 1) to cause mitochondrial fragmentation and cell death (10), but the requirement for PGAM5, Drp1, and mitochondria for necroptosis has been questioned (1, 11–13).We described the structure of mouse MLKL revealing that MLKL contains a C-terminal pseudokinase domain and an N-terminal four-helix bundle (4HB) domain connected by a two-helix linker (the “brace” helices) (1). Based on our mutational and biochemical analyses, we proposed that the catalytically inactive pseudokinase domain functions as a molecular switch and that RIPK3-mediated phosphorylation triggers this switch by inducing a conformational change in MLKL (1, 14).Recently it has been proposed that the 4HB domain is the death effector domain within MLKL and that the killing function of MLKL relies on its oligomerization and plasma membrane association (15–18). The stoichiometry of the oligomer is, however, contentious and has been reported to contain three (15), four (16), and possibly six (17) MLKL protomers. Furthermore, several mechanisms for how this oligomer causes cell death have been proposed: Cai et al. proposed it activates the calcium channel protein Tprm7 and promotes calcium influx (15), Chen et al. showed it increased sodium influx (16), and Wang et al. proposed that the oligomerized form of MLKL has the ability to bind negatively charged lipids, including phosphoinositides and cardiolipin, which facilitates its disruption of membrane integrity (17), a model supported by a subsequent paper (18).Here, we show that the MLKL 4HB domain is sufficient to induce necroptosis and identify several charged residues clustered on two faces that are required for this function. Surprisingly the polarity of several of these charged residues is not conserved between mouse and human MLKL, and alanine substitution of negatively charged residues on the α4 helix of the 4HB domain disrupted function. This finding challenges the importance of phospholipid binding to the killing activity of the 4HB domain and illustrates that membrane association cannot solely be attributed to the interaction of poorly conserved basic residues within the MLKL 4HB domain. Intriguingly, mutation of a second cluster of residues on the 4HB domain did not preclude membrane localization or oligomerization but did prevent cell death, illustrating that additional function(s) beyond membrane translocation are required for the 4HB domain to induce cell death. MLKL oligomerization and membrane translocation were also inhibited by a small molecule, compound 1, which we identified on the basis of its affinity for the nucleotide binding site of the MLKL pseudokinase domain. These data support a model for MLKL function whereby the pseudokinase domain of MLKL holds the 4HB domain in check until phosphorylated by RIPK3, which causes a conformational change in the pseudokinase domain to unleash the 4HB domain to oligomerize and associate with membranes. Activation of MLKL can be thwarted by a small MLKL binding molecule, indicating the feasibility of targeting the nucleotide binding or “pseudoactive” sites of pseudokinases, a hitherto unexplored class of therapeutic targets. 相似文献
62.
Donald M. Bushnell Mona L. Martin Michael Scanlon TeChieh Chen Dina Chau Hema N. Viswanathan 《Quality of life research》2014,23(3):897-906
Purpose
To evaluate the equivalence of electronic and paper versions of the Psoriasis Symptom Inventory and to examine measurement properties of the electronic version.Methods
In a prospective, randomized, crossover, non-interventional study in adult subjects (age ≥18 years) with plaque psoriasis conducted over a period of 15 days, subjects were randomized to two groups, completing either the paper or electronic Psoriasis Symptom Inventory daily for 7 consecutive days followed by the alternate version. Equivalence was assessed by the intraclass correlation coefficient (ICC) between both administration modes. Differences in scores were also tested using paired Student’s t test. Measurement properties included internal consistency reliability, test–retest reliability, and convergent and discriminant validity between the Psoriasis Symptom Inventory and (1) disease-specific (Dermatology Life Quality Index) and (2) general health (SF-36v2) status.Results
Eighty subjects [74 % (59/80) moderate-to-severe psoriasis; 26 % (21/80) mild psoriasis receiving systemic treatment] were enrolled from 8 sites in the USA. The two modes were highly concordant for both total (ICC = 0.97) and individual item scores (ICC range = 0.93–0.97). Response bias testing showed no differences based on completion order with all ICC values >0.91. All mean score differences, except for one item (“flaking”), were non-significant (P > 0.05). Minimum values for reliability (>0.70) and validity (convergent, r ≥ 0.40) were exceeded for the electronic Psoriasis Symptom Inventory.Conclusions
Equivalence between paper and electronic versions of the Psoriasis Symptom Inventory and strong measurement properties of the electronic mode indicated a successful migration from paper to electronic format of the Psoriasis Symptom Inventory. 相似文献63.
The miR‐137 schizophrenia susceptibility variant rs1625579 does not predict variability in brain volume in a sample of schizophrenic patients and healthy individuals
下载免费PDF全文
![点击此处可从《American journal of medical genetics. Part B, Neuropsychiatric genetics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
64.
Placebo controls play a critical role in the evaluation of any pharmacotherapy. This review surveys the placebo arm in 12 randomized controlled trials (RCTs) investigating burning mouth syndrome (BMS) and documents a positive placebo response in 6 of them. On average, treatment with placebos produced a response that was 72% as large as the response to active drugs. The lack of homogeneity in the use of placebos adds to the difficulty in comparing results and aggregating data. Future RCTs investigating BMS would benefit from larger sample sizes, adequate follow‐up periods, and use of a standard placebo. 相似文献
65.
PHILIPPE MAURY M.D. EMILIE THOMSON M.D. ANNE ROLLIN M.D. MATHIEU BERRY M.D. THOMAS COGNET M.D. ALEXANDRE DUPARC M.D. PIERRE MONDOLY M.D. MATHIEU GAUTIER M.D. OLIVIER LAIREZ M.D. SIMON MÉJEAN M.D. PIERRE MASSABUAU M.D. CHRISTELLE CARDIN M.D. STÉPHANE COMBES M.D. JEAN‐PAUL ALBENQUE M.D. NICOLAS COMBES M.D. 《Pacing and clinical electrophysiology : PACE》2015,38(5):617-624
66.
Granulocytic sarcoma of the small intestine preceding acute myelomonocytic leukemia with abnormal eosinophils and inv(16) 总被引:1,自引:0,他引:1
S J Russell F J Giles D S Thompson D J Scanlon H Walker J D Richards 《Cancer Genetics and Cytogenetics》1988,35(2):231-235
We report a case of preleukemic granulocytic sarcoma of the small intestine preceding the development of acute myelomonocytic leukemia with abnormal eosinophils and inversion of chromosome 16, inv(16)(p13q22). A literature review suggests that this is a recurring cytogenetic-clinicopathologic association and carries a favorable prognosis, especially if treated aggressively with antileukemic therapy at the time of diagnosis. 相似文献
67.
艾滋病合并隐球菌脑膜炎18例临床分析 总被引:6,自引:1,他引:6
目的 提高对艾滋病 (AIDS)合并隐球菌脑膜炎的认识。方法 对赤道几内亚巴塔地区医院 18例AIDS合并隐球菌脑膜炎患者进行临床综合分析。结果 18例AIDS合并隐球菌脑膜炎患者的临床主要表现为 :发热、剧烈头痛、极度乏力、肢体痛、脑膜刺激征及消瘦与脱水等。脑脊液 (CSF)培养均为新型隐球菌生长 ;涂片及隐球菌多糖荚膜抗原 (ELISA法 )检测的阳性率分别为 77 8% (14/ 18) ,94 4% (17/ 18)。结论 隐球菌脑膜炎为AIDS常见机会性感染及主要致死病因之一。 相似文献
68.
69.
70.
Jon B. Christianson Karen M. Volmar Jeffrey Alexander Dennis P. Scanlon 《Journal of general internal medicine》2010,25(11):1235-1241